# Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

> **NCT03913182** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Apatinib
- Recurrence
- Metastasis

## Interventions

- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT03913182
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-02
- **Primary completion:** 2020-05-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913182, "Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03913182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*